Inverness, in my opinion, is being quite clever. They have paid for a "semi-exclusive" license but if Recaf works out well, they will have, for all intents and purposes, a virtual monopoly and huge head start on the profits. They may even have the potential to outmanuever Abbott (a senile giant) and we may even behold the spectacle of Abbott coming crawling to them. That one million dollars may turn out to be a very sensible, if not downright cheap, gamble because IF Recaf turns out to be a blockbuster, even any future "semi-exclusive" licensee will be so far behind and may have to go to use Inverness's proprietary reagents after all. There is a possibility that Biocurex will have made much more from Abbott based on its license deal if Abbott went ahead, than Biocurex will make on Inverness (though, obviously it will save Biocurex and make all but the greedy, quite whole). In my opinion, regardless of outcome, Inverness, has been much $marter than Abbott.
